1
Antibody Discovery
Anti-glycan monoclonal antibodies are sourced from GlycoNex's proprietary GlycoSH library, accumulated continuously since 2001 — providing the targeting specificity foundation for every ADC candidate.
TECHNOLOGY · GLYCAN-DIRECTED ADCs
Glycan-Directed Antibody-Drug Conjugates
Antibody-drug conjugates that exploit tumor-specific carbohydrate biology — validated by Japan PMDA's Phase 1 clearance of lead candidate GNX1021 in April 2026.
Foundation
Building on Two Decades of Glycobiology
Building on GlycoNex's two-decade foundation in tumor-associated carbohydrate antigen (TACA) biology — see the Technology overview for the full historical context — these glycan-directed ADC programs pair GlycoNex's anti-glycan antibodies with clinically validated linker technology to translate antibody-glycan recognition into clinical-stage therapeutics.
Tumor cells frequently display aberrant glycosylation during malignant transformation, proliferation, metastasis, and immune escape — producing surface carbohydrate structures markedly distinct from those on healthy cells. These tumor-associated carbohydrate antigens can be distributed across multiple glycoprotein and glycolipid molecules, allowing anti-glycan antibodies to engage tumor cells with higher density and multiple-site binding. This biological asymmetry offers an opportunity to broaden tumor selectivity, enhance antitumor activity, and mitigate resistance pathways that often limit single-target protein-directed therapies.
This approach reached the clinic in April 2026, when Japan's Pharmaceuticals and Medical Devices Agency (PMDA) cleared lead candidate GNX1021 for first-in-human Phase 1 trials in patients with gastrointestinal cancers. Taiwan IND submission is anticipated in Q2 2026.
How It Works
From Antibody Library to Tumor-Selective Delivery
2
Conjugation
Each anti-glycan antibody is conjugated to a cytotoxic payload using clinically validated linker technology — established ADC chemistry selected for serum stability, tumor delivery, and controlled intracellular release.
3
Tumor-Selective Delivery
On tumor-cell engagement, the ADC internalizes, the linker is cleaved within the cellular environment, and the released cytotoxic payload drives tumor-cell death — concentrated at lesions overexpressing the glycan target while sparing healthy tissue with minimal target expression.
The distinguishing feature of this approach is the choice of antigen class. Carbohydrate antigens overexpressed on cancer cells are often minimally expressed on healthy tissue, offering a tumor-selectivity advantage that conventional protein-targeted ADCs cannot easily access.
Because a single tumor cell can display the same carbohydrate epitope across multiple glycoprotein and glycolipid scaffolds, anti-glycan ADCs can achieve higher-density engagement per cell — a property that may translate into improved payload delivery and reduced resistance compared to single-protein-epitope approaches.
Differentiation
Versus Conventional Protein-Targeted ADC Designs
Broader tumor coverage
Carbohydrate antigens can identify tumor populations that lack overexpression of the limited number of established protein targets in clinical ADC development, expanding the addressable patient pool.
Higher tumor selectivity
Many tumor-associated carbohydrate antigens are minimally expressed on healthy tissue, supporting a wider therapeutic window than approaches targeting proteins with broader physiological roles.
Resistance mitigation potential
Multi-site, high-density antibody engagement across glycoprotein and glycolipid scaffolds may reduce susceptibility to resistance mechanisms that emerge when single-epitope protein targets are evaded or down-regulated.
Companion diagnostic readiness
GlycoNex's GlycoBind glycan-detection platform (established 2014) supports companion biomarker development — enabling patient stratification by antigen expression rather than relying on broad histological criteria.
Pipeline Applications
Drugs Built on These Antibodies
Validation
Scientific and Regulatory Validation
Peer-Reviewed Science
GlycoNex's glycan-ADC research includes preclinical data on GNX1021 presented at AACR 2025 and AACR-NCI-EORTC 2025, alongside pro-antibody ADC validation published in the International Journal of Biological Macromolecules (Impact Factor 8.5).
View publications →Patent Portfolio
Nine patents granted for the GNX1021 / GNX102 antibody family, with ten further applications pending (as of June 2026), spanning therapeutic antibodies, conjugate compositions, and treatment uses — part of a broader GlycoNex patent portfolio across multiple programs.
Patent overview →Clinical Translation
Japan PMDA Phase 1 clearance for GNX1021 (April 2026). Taiwan IND submission anticipated Q2 2026. Translational research collaboration with Hokkaido University Hospital on gastric-cancer bLeB/Y expression patterns.
View GNX1021 detail →